

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/752,411
Filing Date	01/07/2004
First Named Inventor	Karen Jackson
Art Unit	1614 1611
Examiner Name	Not Yet Assigned J Kudla
Attorney Docket Number	330499-00025

Sheet 1 of 3

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
/J.K./ ↓		US- 5,550,126	08-27-1996	Horwell et al.	
		US- 5,760,032	06-02-1998	Kitajima et al.	
		US- 5,798,353	08-25-1998	Badorc et al.	
		US- 2003/0139396 A1	07-24-2003	Gibson	
		US- 6,344,452 B1	02-05-2002	Shinozaki et al.	
		US- 2004/0043990 A1	03-04-2004	Jackson	
/J.K./		US- 5,153,191	10-06-1992	Woodruff	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
/J.K./		WO99/18967	04-22-1999	Therapeutics Limited		
/J.K./		WO03/061632	07-31-2003	Karen Jackson		
/J.K./		EP 0 517 412	12-09-1992	Merck Sharp & Dohme		
/J.K./		EP 0 434 364	06-26-1991	Merk & Co Inc.		

Examiner Signature	/Joseph Kudla/	Date Considered	01/15/2008
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

MAY 04 2004  
PATENT & TRADEMARK OFFICE

PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

3

## **Complete if Known**

Application Number	10/752,411
Filing Date	January 7, 2004
First Named Inventor	Karen Jackson
Art Unit	1614-1611
Examiner Name	Not Yet Assigned J Kudla
Attorney Docket Number	330499-00025

## **NON PATENT LITERATURE DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/J.K./		L. BUENO, Involvement of brain CCK in the adaptation of gut motility to digestive status and stress: A review, J Physiology (1993) vol. 87, pp. 301-306	
/J.K./		J. FIORAMONTI, et al., Involvement of a CCK-dependent capsaicin-sensitive afferent pathway in the inhibitory effect of pinaverium bromide on the colonic motor response to eating in rats, Fundam Clin Pharmacol 1997;11:231-236	
		<del>C. BEGLINGER, Effect of Cholecystokinin on Gastric Motility in Humans, Annals New York Academy of Sciences, Vol 713, Issue 1, pp. 219-225</del>	
/J.K./		M. D'AMATO, et al., Cholecystokinin-A receptor antagonists: therapies for gastrointestinal disorders, Exp. Opin. Invest. Drugs (1997) 6(7) pp. 819-836	
		J.G. WETTSTEIN, et al., CCK Antagonists: Pharmacology And Therapeutic Interest, Pharmac. Ther., (1994), vol 62, pp. 267-282	
		WILLIAMS, CYNTHIA et al., Cholecystokinin-induced antinociception is not blocked by CCK-A or CCK-B receptor antagonists, Peptides(Terrytown), 18(3) 1997 pp.409-414	
		SINGH, L. et al., Modulation of the in vivo actions of morphine by the mixed CCKA/B receptor antagonist PD 142898, European Journal of Pharmacology, Amsterdam, NL, 307(3) 1996, pp. 283-289	
		C.T. DOURISH et al., The Cholecystokinin Receptor Antagonist Devazepide Enhances Morphine-Induced Respiratory Depression in the Squirrel Monkey, The Journal of Pharmacology and Experimental Therapeutics, vol. 255, No. 3, 1990, pp. 1158-1164	
/J.K./		JOEL HARDMAN et al., Goodman & Gilman's The Pharmacological basis of Therapeutics, 9th Edition, 1996, pp. 526-529 and 540-545	

Examiner Signature	/Joseph Kudla/	Date Considered	01/15/2008
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/752,411
Filing Date	January 7, 2004
First Named Inventor	Karen Jackson
Art Unit	1614 1611
Examiner Name	Not Yet Assigned J Kudla
Attorney Docket Number	330499-00025

Sheet 3 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/J.K./		SHIPTON, South African J. Anesthesiology & Analgesia, Vol 6, #2, pp. 1-12, 2000	
/J.K./		CHANG et al., Proc. Natl. acad. Sci. USA, Vol. 83, pp. 4923-26, 1986	

Examiner Signature	/Joseph Kudla/	Date Considered	01/15/2008
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.